Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Trial Profile

Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2018

At a glance

  • Drugs EMD 640744 (Primary) ; Dendritic cell vaccines; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
    • 20 Jan 2014 This trial is expected to start in the first half of 2014, according to a Immunovaccine media release.
    • 04 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top